by Greg Kuehn | Sep 5, 2019 | Press Releases
CARLSBAD, Calif., Sept. 4, 2019 /PRNewswire/ — Prescient Metabiomics, a privately held company and a subsidiary of Prescient Medicine Holdings, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted the company’s submission...
by Greg Kuehn | Sep 18, 2018 | Press Releases
Innovative new microbiome GI health solutions battle colon cancer and gastrointestinal disease Chicago, Sept. 18, 2018 – Prescient Medicine Holdings, LLC and Metabiomics Corp., have announced a joint venture to develop an innovative microbiome diagnostics platform for...
by Greg Kuehn | Feb 26, 2018 | Press Releases
In a recent article by Suzanne Elvidge, published in BiopharmaDIVE, Metabiomics was highlighted as a clinical development leader that is exploring the links between microbiota and colon cancer. The article, titled “Hunting for the ‘good’ and...
by Greg Kuehn | Jun 19, 2017 | Press Releases, Research News
Manassas, VA, June 19, 2017 – Metabiomics is proud to announce the completion of one of the largest case-controlled studies on the colorectal polyp microbiome. Titled “Metabiomics Neoplasia Clinical Research Study”, also referred to as MB-01 by Metabiomics, the...
by Greg Kuehn | Dec 16, 2015 | Press Releases
PRESS RELEASE Cambridge, UK and Aurora, CO December 16, 2015 Metabiomics Corp. announced it has secured a distribution agreement with Origin Sciences pursuant to which it will develop, test, and commercialize the novel OriCol™ gastrointestinal sampling technology for...
by Greg Kuehn | Sep 10, 2015 | Press Releases
San Diego, CA September 10, 2015 Metabiomics is pleased to be attending the 3rd annual Global Engage Microbiome R&D and Business Collaboraton Forum. Greg Kuehn, President and COO will be giving a talk on Day 2 (sept 11) covering the...
